Related Experiment Videos
The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia
1Department of Internal Medicine King/Drew Medical Center, Los Angeles, California 90059, USA.
Insights
Lovastatin effectively lowered total cholesterol and LDL cholesterol in African Americans with high cholesterol. This HMG-CoA reductase inhibitor shows promise for managing cardiovascular risk in this population.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- African Americans (AA) face a higher risk of hypertension and cardiovascular disease.
- Primary hypercholesterolemia is a significant risk factor for cardiovascular morbidity.
- Effective cholesterol-lowering strategies are crucial for the AA population.
Purpose of the Study:
- To assess the efficacy of lovastatin in treating primary hypercholesterolemia in African Americans.
- To evaluate lovastatin's impact on lipid profiles in this specific demographic.
Main Methods:
- A double-blinded, placebo-controlled trial involving 47 African American patients.
- Patients received either lovastatin (20 mg/day) or a placebo for 10 weeks.
- Dietary counseling on a low-fat, low-cholesterol diet was provided to all participants.
Main Results:
- Lovastatin significantly reduced mean total cholesterol (14.7%) and LDL cholesterol (20.0%) (P < 0.01).
- A 10.5% decrease in triglyceride levels was observed, though not statistically significant.
- No significant changes in hepatic transaminase levels were noted in either group.
Conclusions:
- Lovastatin (20 mg/day) is effective in lowering total cholesterol, LDL, and triglyceride levels in African Americans.
- Increased utilization of HMG-CoA reductase inhibitors is recommended for managing elevated cholesterol in the AA population.
- Addressing hypercholesterolemia in AA individuals is vital due to their elevated cardiovascular risk.
Purpose:
To evaluate the efficacy of lovastatin in African Americans (AA) diagnosed with primary hypercholesterolemia.
Patients And Methods:
Forty-seven AA patients from the King/Drew Medical Center in Los Angeles were recruited from the Hypertension, Family Practice, and General Medicine Clinics for a double-blinded, placebo-controlled trial. Forty-one patients completed the 10 week study. Eligibility for entrance into the study was determined by patient lipid profiles meeting the criteria for pharmacological intervention outlined by the National Cholesterol Education Program II guidelines. Patients were randomized into 2 groups: lovastatin 20 mg per day, or placebo. A registered dietitian counseled both groups on two visits during the study to ensure compliance with a low fat, low cholesterol diet. Lipid levels were compared at the first and last visit of the study.
Results:
The lovastatin-treated group demonstrated significant reductions in mean total cholesterol (TC) (14.7%, 95% confidence interval [CI]-6.6 to -22.8, P < 0.01) and low-density lipoprotein (LDL) cholesterol (20.0%, 95% CI-7.9 to -32.1, P < 0.01) from baseline. Plasma triglyceride (TG) levels decreased by 10.5% (95% CI-2.4 to -18.6) and total cholesterol/high density lipoprotein (HDL) ratio fell below five in the lovastatin group, but neither reduction reached statistical significance. Placebo administration was not associated with any significant changes in TC, LDL, or TG. There were no significant differences between baseline and post-treatment hepatic transaminase levels in either group.
Conclusions:
The HMG-CoA (3-hydroxyl-3 methylglutary coenzyme A) reductase inhibitor lovastatin in a dose of 20 mg per day was effective in decreasing TC, LDL, and TG levels in an AA population. Considering that the AA population is at substantially increased risk for hypertension and cardiovascular morbidity, more aggressive and wider use of HMG-CoA reductase inhibitors should be employed in reducing elevated plasma cholesterol levels.